| Autor: |
Andrioaie IM; Department and Preventive Medicine and Interdisciplinarity (IX)-Microbiology, Faculty of Medicine, 'Grigore, T. Popa' University of Medicine and Pharmacy, 700115 Iasi, Romania., Luchian I; Department of Periodontology, Faculty of Dental Medicine, 'Grigore T. Popa' University of Medicine and Pharmacy, 700115 Iasi, Romania., Dămian C; Department and Preventive Medicine and Interdisciplinarity (IX)-Microbiology, Faculty of Medicine, 'Grigore, T. Popa' University of Medicine and Pharmacy, 700115 Iasi, Romania., Nichitean G; Department of Periodontology, Faculty of Dental Medicine, 'Grigore T. Popa' University of Medicine and Pharmacy, 700115 Iasi, Romania., Andrese EP; Department of Medical Specialties (III)-Dermatology, Faculty of Medicine, 'Grigore T. Popa' University of Medicine and Pharmacy, 700115 Iasi, Romania., Pantilimonescu TF; Department of Morpho-Functional Sciences II-Physiology, 'Grigore T. Popa' University of Medicine and Pharmacy, 700115 Iasi, Romania., Trandabăț B; Department of Ortopedy-Traumatology, 700115 Iasi, Romania., Prisacariu LJ; Clinical Hospital of Infectious Diseases 'Sf. Parascheva', 700116 Iasi, Romania., Budală DG; Department of Removable Dentures, Faculty of Dental Medicine, 'Grigore T. Popa' University of Medicine and Pharmacy, 700115 Iasi, Romania., Dimitriu DC; Department of Biochemistry, 'Grigore T. Popa' University of Medicine and Pharmacy, 700115 Iasi, Romania.; Gynecology and Obstetrics Hospital-Cuza Voda, 700038 Iasi, Romania., Iancu LS; Department and Preventive Medicine and Interdisciplinarity (IX)-Microbiology, Faculty of Medicine, 'Grigore, T. Popa' University of Medicine and Pharmacy, 700115 Iasi, Romania., Ursu RG; Department and Preventive Medicine and Interdisciplinarity (IX)-Microbiology, Faculty of Medicine, 'Grigore, T. Popa' University of Medicine and Pharmacy, 700115 Iasi, Romania.; Gynecology and Obstetrics Hospital-Cuza Voda, 700038 Iasi, Romania. |
| Abstrakt: |
Human papillomavirus (HPV) is recognized as being related to a wide variety of known cancers: cervical, oropharyngeal, anal, vaginal, penile, and skin. For some of these cancers, rigorous algorithms for screening, therapeutical interventions, and follow-up procedures have been established. Vaccination using the nonvalent anti-HPV vaccine, which prevents infection regarding the most frequently involved high-risk HPV types (16, 18, 31, 33, 45, 52, and 58) and low-risk HPV types (6 and 11), has also extensively prevented, controlled, and even eradicated HPV infections. Still, even with all of these multidisciplinary interventions, the burden of HPV cancers is still high worldwide. The circulating DNA of HPV-induced cancers is thought to be an adequate biomarker for optimizing the control of these virus-related cancers. We analyzed the literature published in the last 5 years regarding ctDNA and four of the above-mentioned cancers. The most frequently used assay for ctDNA detection was the droplet digital PCR assay, used for the management of therapy in the late stages of cancer. ctDNA could not be used for early detection in any of the studied cancers. The OPSCCs were the most frequent cancers analyzed via ctDNA assays. Larger, properly designed cohort studies might establish the clinical utility of this biomarker. |
